Lifirafenib

N/A

Report date: 2026/04/30 20:00:20
NME

Base Information

Drug NameLifirafenib
Drug Alias NameBGB-283-sesqui-maleateLifirafenib maleateBeiGene-283BGB-283
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionB-raf V600E inhibitorsSerine/threonine-protein kinase B-raf inhibitorsC-Raf kinase inhibitors +[5] 
TargetsEpidermal growth factor receptor erbB1B-raf V600ESerine/threonine-protein kinase B-raf +[5] 
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNew ZealandAustralia +[4] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPending
Originator CompaniesBeOne Medicines Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesBeOne Medicines Ltd
Inactive CompaniesBeOne Medicines (Beijing) Co Ltd
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A